TRT for Depression: Does Testosterone Therapy Actually Improve Mood?

What is the Link Between Low Testosterone and Depression?

Testosterone acts on androgen receptors throughout the limbic system, including the hippocampus and amygdala, areas that govern emotional memory, stress response, and reward signaling. When circulating testosterone falls below 300 ng/dL, these circuits lose their normal hormonal input and mood changes follow reliably. The Endocrine Society's 2018 Clinical Practice Guideline defines male hypogonadism as "a clinical syndrome that results from failure of the testes to produce physiological concentrations of testosterone" and specifies that the diagnosis requires both symptoms and biochemical confirmation on two separate morning samples [1].

Epidemiological data support a real bidirectional relationship. A cross-sectional analysis of 3,987 men in the European Male Ageing Study (EMAS) found that men with total testosterone below 8 nmol/L (roughly 230 ng/dL) had significantly higher odds of depressive symptoms compared with eugonadal peers (OR 2.35 to 95% CI 1.37-4.04) [2]. Depression, in turn, suppresses gonadotropin-releasing hormone pulsatility at the hypothalamus, lowering LH and FSH signals to the testes. The result is a self-reinforcing cycle that standard antidepressants alone may not fully break.

Andropause, also called late-onset hypogonadism, describes the gradual testosterone decline that begins around age 35 and accelerates after 50. Total testosterone drops roughly 1-2% per year after age 30, according to the Baltimore Longitudinal Study of Aging [3]. By age 70, approximately 30% of men meet biochemical criteria for hypogonadism [4]. Depressive symptoms during this window are often misattributed to life stress or "normal aging" rather than screened as a hormone disorder.

What Does the Clinical Trial Evidence Say?

The strongest pooled estimate comes from a 2019 meta-analysis by Walther and colleagues, published in JAMA Psychiatry, which examined 27 RCTs enrolling 1,890 men randomized to testosterone versus placebo [5]. Testosterone produced a small but statistically significant reduction in depressive symptoms (SMD 0.21 to 95% CI 0.10-0.32, P<0.001). Effect size was larger in subgroups with confirmed hypogonadism (SMD 0.29) and in men who were not concurrently taking antidepressants.

The Testosterone Trials (TTrials), a coordinated set of seven double-blind RCTs funded by the NIH and conducted across 12 US sites, enrolled 790 men aged 65 or older with total testosterone below 275 ng/dL [6]. The Vitality Trial within that consortium found testosterone gel (targeting levels of 500-800 ng/dL) produced modest but statistically significant improvements in energy and mood scores on the SF-36 vitality sub-scale at 12 months versus placebo (P<0.001) [6]. The Sexual Function Trial within TTrials found statistically significant improvements in libido and sexual activity in the testosterone arm compared with placebo [7].

A smaller but clinically informative 2018 RCT by Khera and colleagues (N=80) tested testosterone undecanoate 1 to 000 mg IM at 0, 6, and 18 weeks in men with major depressive disorder and confirmed hypogonadism already on SSRIs [8]. At 26 weeks, 52.5% of testosterone-treated men achieved remission (PHQ-9 <5) versus 22.5% in placebo. That 30-percentage-point gap suggests TRT may substantially improve antidepressant response rates when low T is the underlying contributor.

Not every trial is positive. The TRAVERSE cardiovascular safety trial (N=5,204), the largest TRT RCT to date, was not designed to measure depression as a primary outcome, though participants did report improved sexual function [9]. The FDA approved testosterone products for hypogonadism, not for depression specifically, so off-label depressive symptom improvement remains a documented secondary benefit rather than a primary indication [10].

Primary vs Secondary Hypogonadism: Why the Distinction Matters for Treatment

Correctly classifying hypogonadism as primary or secondary changes the treatment approach significantly. Primary hypogonadism means the testes themselves are failing; LH and FSH rise because the pituitary tries to compensate. Causes include Klinefelter syndrome, orchitis, or prior chemotherapy. Secondary (central) hypogonadism means the hypothalamic-pituitary axis is suppressed or dysfunctional; LH and FSH are inappropriately low or normal despite low testosterone. Causes include hyperprolactinemia, obesity, opioid use, and pituitary adenoma.

Men with secondary hypogonadism who want to preserve fertility may be candidates for clomiphene citrate or human chorionic gonadotropin (hCG) instead of, or alongside, exogenous testosterone [1]. Testosterone replacement suppresses the pituitary-testicular axis and reduces sperm production within weeks. A 2021 review in the Journal of Clinical Endocrinology and Metabolism confirmed that intramuscular testosterone reduces sperm concentration to below 1 million/mL in roughly 70% of men within 6 months [11].

For mood and depression specifically, both primary and secondary hypogonadism can produce identical depressive symptoms. What matters for treatment selection is fertility intent and the underlying cause of the low LH/FSH, not the mood phenotype.

How TRT Improves Libido and Sexual Desire

Low libido is among the most common and distressing symptoms of hypogonadism. Testosterone drives sexual desire through androgen receptor activity in the medial preoptic area of the hypothalamus and through modulation of dopaminergic pathways in the nucleus accumbens. When T falls below roughly 300 ng/dL, central drive drops measurably before peripheral erectile function is affected.

The TTrials Sexual Function Trial found that men randomized to testosterone gel had significantly higher scores on the Psychosexual Daily Questionnaire for sexual desire compared with placebo at 12 months (mean difference 1.0 point on a 1-5 scale, P<0.001) [7]. A separate systematic review of 29 trials (N=4,202) published in the Journal of Sexual Medicine in 2017 found that testosterone therapy improved total and domain-specific International Index of Erectile Function (IIEF) scores, with the largest effect on the desire domain (weighted mean difference 1.5 points) [12].

Response typically appears within 3-6 weeks of reaching therapeutic testosterone levels (400-700 ng/dL). Men who do not notice libido improvement after 3 months of confirmed therapeutic levels should be evaluated for other contributors: relationship factors, hyperprolactinemia, thyroid dysfunction, or major depressive disorder requiring dedicated treatment.

TRT and Erectile Dysfunction: What Testosterone Can and Cannot Do

Erectile dysfunction and low libido are related but mechanistically distinct. An erection requires intact nitric oxide signaling in penile endothelium, normal vascular tone, and sufficient penile blood flow, with testosterone playing a permissive rather than a primary role in most cases. The Massachusetts Male Aging Study, which followed 1,709 men over 8.8 years, found that low testosterone was associated with ED (OR 1.6) but that vascular disease, diabetes, and age carried far larger effect sizes [13].

Testosterone therapy alone improves erectile function best when hypogonadism is the primary driver, total T is below 230 ng/dL, and vascular risk factors are minimal. A 2016 meta-analysis by Isidori and colleagues (N=1,473 across 14 trials) found testosterone improved IIEF erectile function domain scores by a mean of 3.7 points versus placebo, a clinically meaningful change on a scale where the minimally important difference is 2 points [14].

For most men with ED and low-normal testosterone (230-350 ng/dL), adding a PDE5 inhibitor such as sildenafil 50-100 mg or tadalafil 5 mg daily alongside TRT produces better outcomes than either therapy alone. A 2014 RCT published in BJU International (N=140) found that combination testosterone plus tadalafil improved IIEF scores by 7.3 points versus 4.1 points for tadalafil alone in hypogonadal men (P<0.05) [15].

Men with severe ED and cardiovascular disease should be evaluated by a urologist before initiating either therapy.

Standard TRT Protocols and Dosing for Mood and Sexual Function

Several formulations are FDA-approved for hypogonadism and have been studied in mood and sexual function trials [10].

Testosterone cypionate or enanthate (injectable): The most commonly prescribed option in the United States. Typical dosing is 100-200 mg intramuscularly every 1-2 weeks, or 50-100 mg weekly to minimize peak-to-trough swings. The T Trials used transdermal gel, but injectable formulations are preferred in clinical practice for cost and adherence reasons.

Testosterone gel 1.62% (AndroGel, Testim): Applied daily to shoulders or upper arms. Starting dose is 40.5 mg/day (2 pumps), titrated based on trough levels drawn 2 weeks after initiation. Used in TTrials due to ease of titration in research settings [6].

Testosterone undecanoate 750 mg IM (Aveed): Given at 0, 4, and then every 10 weeks. A single injection covers approximately 10 weeks. Long-term adherence data are favorable but it carries an FDA REMS requirement due to rare pulmonary oil microembolism [10].

Clomiphene citrate 25-50 mg orally three times per week: Off-label, used in secondary hypogonadism when fertility preservation is desired. Stimulates endogenous LH and FSH rather than replacing testosterone exogenously.

Target serum total testosterone is generally 400-700 ng/dL for symptomatic relief, with free testosterone kept in the upper one-third of the normal range for age. The Endocrine Society guideline advises against targeting levels above 700 ng/dL without specific clinical justification [1].

Monitoring: What Labs to Track and When

Regular monitoring reduces the risk of polycythemia, cardiovascular events, and prostate-related complications. The Endocrine Society recommends checking haematocrit, PSA, and total testosterone at 3-6 months after initiating therapy, then annually once stable [1].

Haematocrit above 54% requires dose reduction or temporary cessation; elevated haematocrit raises blood viscosity and thrombosis risk. The TRAVERSE trial, published in the New England Journal of Medicine in 2023, found that testosterone therapy was associated with a higher incidence of atrial fibrillation (3.5% vs 2.4%), pulmonary embolism (0.9% vs 0.5%), and acute kidney injury versus placebo over a median 33-month follow-up [9]. These findings prompted the FDA to update testosterone prescribing information in 2024 to include cardiovascular and thromboembolic risk language [10].

PSA should be checked at baseline, 3-6 months, and annually. A rise of more than 1.4 ng/mL above baseline in any 12-month period warrants urology referral per American Urological Association guidance.

Who Responds Best to TRT for Depressive Symptoms?

Evidence from the 2019 Walther meta-analysis and the TTrials points to several factors that predict a stronger antidepressant response from TRT [5][6]:

Total testosterone below 300 ng/dL on two morning draws confirms biochemical hypogonadism. Symptom onset correlating with the decline in testosterone, rather than preceding it, suggests hormonal causation. Age 40-65 represents the window of late-onset hypogonadism where testosterone-mood connections are most direct. Men not already on SSRIs or SNRIs at baseline showed larger effect sizes in Walther's meta-analysis. Comorbid low libido and fatigue alongside depressive symptoms also predict better mood response to TRT, since those symptoms are more specific to androgen deficiency.

Men with moderate-to-severe major depressive disorder defined by DSM-5 criteria, even if they have low testosterone, generally need dedicated psychiatric care alongside TRT rather than TRT alone. The American Psychiatric Association's 2022 Practice Guideline for Major Depressive Disorder does not list testosterone as a first-line or augmentation therapy, though it acknowledges the role of hormonal evaluation in treatment-resistant cases [16].

TRT Versus Antidepressants: A Direct Comparison

SSRIs and SNRIs remain the first-line pharmacological treatment for major depressive disorder in men, regardless of testosterone status. Fluoxetine, sertraline, and escitalopram each carry NNTs (numbers needed to treat) of roughly 7-9 for remission in meta-analyses of placebo-controlled trials [17]. TRT's NNT for depressive symptom reduction in confirmed hypogonadal men is approximately 5-6 based on the Khera 2018 trial data, though this estimate is from a smaller dataset [8].

The two approaches are not mutually exclusive. TRT and SSRIs act through different neurobiological routes, and combination use in hypogonadal depressed men produced the best remission rates in the Khera trial (52.5% remission vs 22.5% for placebo, with both groups continuing SSRIs) [8]. For men whose depression does not respond to adequate SSRI therapy and who have untested testosterone levels, a morning total testosterone draw is a low-cost, high-yield next step.

One practical concern: SSRIs and SNRIs can themselves cause low libido and delayed ejaculation in 30-40% of users [18]. If low libido emerges after starting an antidepressant, it may reflect medication side effects rather than hypogonadism, and measuring testosterone levels before assuming a hormonal cause is standard care.

Andropause and Mood: Recognizing the Clinical Picture

Andropause refers informally to the cluster of symptoms that accompany declining testosterone in middle-aged and older men. The clinical picture overlaps substantially with depression: low energy, reduced motivation, irritability, sleep disruption, weight gain, and loss of interest in activities. The key differentiating features that raise suspicion for a hormonal rather than purely psychological cause are concurrent decreases in morning erections, libido, and testicular volume, along with a gradual rather than episodic onset.

The EMAS defined late-onset hypogonadism using a strict syndromic definition requiring three sexual symptoms (reduced libido, fewer morning erections, erectile dysfunction) plus biochemical confirmation [2]. Using this definition, only 2.1% of men aged 40-79 met full criteria, a much lower prevalence than symptom-only screening suggests. This distinction matters because treating mildly low or low-normal testosterone without confirmed hypogonadism and meaningful symptoms produces no reliable mood benefit and exposes men to unnecessary risk.

Clinicians at HealthRX screen all men presenting with depression and fatigue for hypogonadism using a morning total testosterone draw alongside a sex hormone-binding globulin (SHBG) level to calculate free testosterone. SHBG rises with age and can make total testosterone appear higher than the biologically active free fraction warrants.

Safety Considerations and Contraindications

TRT is contraindicated in men with breast or prostate cancer, haematocrit above 50% at baseline, untreated severe obstructive sleep apnea, and in men actively trying to conceive without concurrent hCG co-administration [1].

The cardiovascular risk signal from TRAVERSE has shifted prescribing practice. Men with pre-existing atrial fibrillation, a history of deep vein thrombosis, or known hypercoagulable states should have a detailed risk-benefit conversation with their physician before starting testosterone [9]. Younger men (age <40) with secondary hypogonadism caused by a reversible factor, such as obesity-related suppression or opioid-induced hypogonadism, are often better served by treating the underlying cause first and rechecking testosterone 3-6 months later rather than starting replacement immediately.

Sleep apnea worsens on TRT due to testosterone's effect on upper airway muscle tone and hypoxic ventilatory response. Men who snore or have daytime sleepiness should complete a sleep study before initiating therapy, as untreated apnea also directly worsens both mood and testosterone production.